GPRC5D CAR T cell therapy - Guangzhou Bio-gene Technology
Alternative Names: Anti-GPRC5D CAR-T cell therapyLatest Information Update: 19 Sep 2024
At a glance
- Originator Guangzhou Bio-gene Technology
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Multiple myeloma
Most Recent Events
- 13 Jun 2024 Efficacy and adverse events data from a phase I/II trial in Multiple myeloma presented at the 29th Congress of the European Haematology Association (EHA-2024)
- 13 Jun 2024 Pharmacodynamics data from a preclinical trial in Multiple myeloma presented at the 29th Congress of the European Haematology Association (EHA-2024)
- 09 Dec 2023 Efficacy and adverse events data from phase-I/II trial in Multiple myeloma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)